4.8 Article

Rapid Blood-Pressure Lowering in Patients with Acute Intracerebral Hemorrhage

期刊

NEW ENGLAND JOURNAL OF MEDICINE
卷 368, 期 25, 页码 2355-2365

出版社

MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMoa1214609

关键词

-

资金

  1. National Health and Medical Research Council of Australia
  2. National Health and Medical Research Council (NHMRC) of Australia [571281, 512402, 1004170]
  3. Australian Research Council
  4. High Blood Pressure Research Council of Australia
  5. Osaka Pharmaceuticals
  6. Novartis
  7. Omron Healthcare
  8. Pfizer
  9. Takeda
  10. AD Pharma
  11. Servier
  12. Lundbeck
  13. BMJ
  14. Bristol-Myers Squibb
  15. Boehringer Ingelheim
  16. Sanofi-Aventis
  17. EVER Neuro Pharma

向作者/读者索取更多资源

Background Whether rapid lowering of elevated blood pressure would improve the outcome in patients with intracerebral hemorrhage is not known. Methods We randomly assigned 2839 patients who had had a spontaneous intracerebral hemorrhage within the previous 6 hours and who had elevated systolic blood pressure to receive intensive treatment to lower their blood pressure (with a target systolic level of <140 mm Hg within 1 hour) or guideline-recommended treatment (with a target systolic level of <180 mm Hg) with the use of agents of the physician's choosing. The primary outcome was death or major disability, which was defined as a score of 3 to 6 on the modified Rankin scale (in which a score of 0 indicates no symptoms, a score of 5 indicates severe disability, and a score of 6 indicates death) at 90 days. A prespecified ordinal analysis of the modified Rankin score was also performed. The rate of serious adverse events was compared between the two groups. Results Among the 2794 participants for whom the primary outcome could be determined, 719 of 1382 participants (52.0%) receiving intensive treatment, as compared with 785 of 1412 (55.6%) receiving guideline-recommended treatment, had a primary outcome event (odds ratio with intensive treatment, 0.87; 95% confidence interval [CI], 0.75 to 1.01; P = 0.06). The ordinal analysis showed significantly lower modified Rankin scores with intensive treatment (odds ratio for greater disability, 0.87; 95% CI, 0.77 to 1.00; P = 0.04). Mortality was 11.9% in the group receiving intensive treatment and 12.0% in the group receiving guideline-recommended treatment. Nonfatal serious adverse events occurred in 23.3% and 23.6% of the patients in the two groups, respectively. Conclusions In patients with intracerebral hemorrhage, intensive lowering of blood pressure did not result in a significant reduction in the rate of the primary outcome of death or severe disability. An ordinal analysis of modified Rankin scores indicated improved functional outcomes with intensive lowering of blood pressure.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据